{"id":"W3133838590","doi":"10.1016/j.jtho.2021.02.010","title":"Crizotinib in Patients With MET-Amplified NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Exelixis; Revolution Medicines; Foundation Medicine; Sierra Oncology; Pfizer; Incyte; Astex Pharmaceuticals; Bayer Fund; AstraZeneca; Novocure; Merck KGaA; Jounce Therapeutics; Ariad Pharmaceuticals; Takeda Pharmaceutical Company; Amgen; Roche; Spectrum Pharmaceuticals; Merck; GlaxoSmithKline; Array BioPharma; G1 Therapeutics; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Fluorescence in situ hybridization; Internal medicine; ROS1; Retrospective cohort study; Gene duplication; Gastroenterology; Progression-free survival; Hazard ratio; Oncology; Confidence interval; Overall survival; Adenocarcinoma; Lung cancer; Gene; Cancer; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003334262,0.0003128314,0.001001099,0.0002681723,0.0002569506,0.0006620602,0.0002487053,0.0004634552,0.001037844],"category_scores_gemma":[0.001061411,0.0001657394,0.0006449122,0.0004713431,0.0001651694,0.0003501586,0.0002236527,0.00097154,0.0002225863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001147365,"about_ca_system_score_gemma":0.0008337318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004702805,"about_ca_topic_score_gemma":0.01733586,"domain_scores_codex":[0.9997216,0.00005620361,0.00003240943,0.00004910972,0.00005395063,0.0000867137],"domain_scores_gemma":[0.9997904,0.0000477982,0.0000516501,0.000007199573,0.00002365258,0.000079449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.05167716,0.0006305751,0.5232024,0.001253962,0.003083701,0.005208962,0.0002430569,0.003809328,0.02649118,0.0006852858,0.01442901,0.3692854],"study_design_scores_gemma":[0.008318097,0.01172121,0.9079635,0.000426793,0.005112401,0.01386584,0.0005996411,0.007194914,0.006654392,0.001419481,0.03661461,0.0001090994],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9508429,0.03531078,0.0002319327,0.002935205,0.0002756776,0.0000726305,0.0009681906,0.00005091591,0.009311752],"genre_scores_gemma":[0.9929041,0.004443591,0.0001780027,0.0007055548,0.0001365537,0.00002262558,0.0007468536,0.000005696623,0.0008569956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004702805,"threshold_uncertainty_score":0.009350896,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0194702299251419,"score_gpt":0.4345962996276041,"score_spread":0.4151260697024622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}